The fair value estimate for Sight Sciences has been reduced from US$9.35 to US$8.40, reflecting more cautious assumptions on growth and profitability. Revenue growth expectations were lowered from 12.96% to 10.68%, while the net profit margin forecast declined from 12.90% to 11.46%. The future P/E multiple increased from 47.39x to 51.65x, and the discount rate was adjusted from 7.92% to 7.60%. UBS resumed coverage with a Buy rating but cut its price target from US$11 to US$7, while Citi raised its target twice in 2026, first to US$5.15 and then to US$6, maintaining a Neutral rating. Analysts noted generally solid conditions in medical technology and eyecare, though refractive procedures remain challenged, potentially limiting valuation upside.
Sight Sciences IncFair value estimate and price targets cut, reflecting lower growth and profitability expectations.
Citigroup Inc.
UBS Group AG